MedPath
HSA Approval

ASMALIN SYRUP 1.5 mg/5 ml

SIN07055P

ASMALIN SYRUP 1.5 mg/5 ml

ASMALIN SYRUP 1.5 mg/5 ml

June 12, 1992

SUNWARD PHARMACEUTICAL PRIVATE LIMITED

SUNWARD PHARMACEUTICAL PRIVATE LIMITED

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantSUNWARD PHARMACEUTICAL PRIVATE LIMITED
Licence HolderSUNWARD PHARMACEUTICAL PRIVATE LIMITED

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Pharmacy Only
HSA Singapore Classification

Formulation Information

SYRUP

ORAL

Medical Information

R03CC03

terbutaline

Manufacturer Information

SUNWARD PHARMACEUTICAL PRIVATE LIMITED

SUNWARD PHARMACEUTICAL PRIVATE LIMITED

SUNWARD PHARMACEUTICAL SDN BHD

Active Ingredients

TERBUTALINE SULPHATE

1.5 mg/5 ml

Terbutaline

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

ASMALIN SYRUP 1.5 mg/5 ml - HSA Approval | MedPath